Clinical trials: Seizures Disorders
Hearing Loss
Evaluation of Extended Wear Technology
Evaluating the efficacy and effectiveness of an advancement in the fitting characteristics of extended wear technology with the commercially available device as a comparator.
- Trial name
- NCT04882800
- Testing
- Lyric extended wear hearing aid device A, Lyric extended wear hearing aid with fitting modification device B
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- Sonova AG
Epilepsy, Partial
Conversion To Monotherapy With Lamictal Extended Release Tablets For Treatment Of Partial Epilepsy
This study is being conducted to determine the effectiveness of a lower monotherapy dose of lamotrigine than that currently approved.
- Trial name
- NCT00355082
- Testing
- lamotrigine, 300 mg/day, lamotrigine, 250 mg/day
- Where
- 103 sites in United States, Argentina and 6 more
- Volunteers
- 226 people
- Sponsor
- GlaxoSmithKline
Epilepsy
Seizure Detection and Automatic Magnet Mode Performance Study
The purpose of this study is to confirm cardiac-based seizure detection in Cyberonics Model 106 VNS Therapy System.
- Trial name
- E-36 (NCT01325623)
- Testing
- Model 106 VNS Therapy System
- Where
- 14 sites in Belgium, Germany and 3 more
- Volunteers
- 31 people
- Sponsor
- Cyberonics, Inc.
Partial Epilepsy
Dose-Escalation Study of Cenobamate (YKP3089) in Pediatric Subjects With Partial-Onset Seizures
The primary objective of this study is to assess the pharmacokinetics of cenobamate (YKP3089) in pediatric subjects with partial-onset (focal) seizures following single and multiple-dosing.
- Trial name
- NCT04903314
- Testing
- Xcopri
- Where
- 13 sites in United States, Hungary and 1 more
- Volunteers
- 26 people
- Sponsor
- SK Life Science, Inc.
Epilepsy
RNS® System Pivotal Study
The RNS® System Pivotal study is designed to assess safety and demonstrate that the RNS® System is effective as an adjunctive (add-on) therapy in reducing the frequency of seizures in individuals 18 years of age or older with…
- Trial name
- NCT00264810
- Testing
- RNS® System implantation, RNS® System responsive stimulation
- Where
- 32 sites in United States
- Volunteers
- 240 people
- Sponsor
- NeuroPace
Epilepsies, Myoclonic
A Study of Lorcaserin as Adjunctive Treatment in Participants With Dravet Syndrome
The primary purpose of the study is to demonstrate that lorcaserin has superior efficacy compared to placebo on percent change in frequency of convulsive seizures per 28 days in participants with Dravet syndrome.
- Trial name
- MOMENTUM 1 (NCT04572243)
- Testing
- Lorcaserin
- Where
- 30 sites in United States, Canada
- Volunteers
- 22 people
- Sponsor
- Eisai Inc.
Epilepsy; Seizure
Forecasting Seizures Using Intelligent Wearable Technology for Health Tracking
The goal of this interventional study is to develop a personalized seizure risk forecast tool in people with epilepsy. The main questions it aims to answer are: can we develop a future seizure probabilities tool that is more…
- Trial name
- Foresight (NCT06275685)
- Testing
- SeizureWise algorithm, Multi-day Visualizations
- Where
- United States
- Volunteers
- 3,000 people
- Sponsor
- Empatica, Inc.
Neuralgia, Epilepsy
Clinical Study With Lyrica In Patients Suffering From Epilepsy
Clinical study with Lyrica (pregabalin) in patients suffering from epilepsy. This drug is used as adjunctive therapy with one or more antiepileptics. Lyrica has potential to reduce seizure frequency.
- Trial name
- NCT00922987
- Testing
- Lyrica (pregabalin)
- Where
- 61 sites in Slovakia
- Volunteers
- 286 people
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Epilepsy
Study to Investigate Dosage, Efficacy, and Safety of Fycompa in Routine Clinical Care of Patients With Epilepsy
This study is conducted to assess the retention rate of Fycompa when given in routine clinical care.
- Trial name
- NCT03208660
- Testing
- Fycompa
- Where
- 44 sites in United States
- Volunteers
- 2,000 people
- Sponsor
- Eisai Inc.
Focal Seizure, Epilepsy
Study Evaluating the Efficacy and Safety of RAP-219 in Adult Participants With Focal Seizures FOCUS-1
This is a clinical research study for an investigational drug called RAP-219 in adult participants with focal seizures. This study is being conducted to determine if RAP-219 is safe and effective in reducing focal seizure…
- Conditions
- Focal Seizure, Epilepsy, Focal Epilepsy
- Trial name
- FOCUS 1 (NCT07563881)
- Testing
- RAP-219
- Where
- 18 sites in United States, South Korea
- Volunteers
- 333 people
- Sponsor
- Rapport Therapeutics Inc.
Epilepsy, Partial Seizures
An Open Label Study of Levetiracetam in Japanese Pediatric Patients With Partial Seizures
Objective of the First Period: To evaluate the efficacy of Levetiracetam dry syrup at doses up to a maximum of 60 mg/kg/day or 3000 mg/day used as an adjunctive therapy in Japanese pediatric patients (4 to 16 years) with…
- Trial name
- NCT01063764
- Testing
- Levetiracetam
- Where
- 29 sites in Japan
- Volunteers
- 73 people
- Sponsor
- UCB Japan Co. Ltd.
Epilepsy
A Dose Ranging Pilot Study for Intracerebroventricular (ICV) Delivery of Valproate in Subjects With Temporal Seizures
Patients with medically refractory epilepsy will be treated by intracerebroventricular (ICV) delivery of valproate using an implantable drug pump system.
- Trial name
- NCT02899611
- Testing
- Valproate
- Where
- Australia
- Volunteers
- 6 people
- Sponsor
- Cerebral Therapeutics LLC
Refractory Epilepsy, Focal Seizure
Pivotal-Safety and Therapeutic Measures of tDCS in Patients With Refractory Focal Epilepsy
This is a multiple site, randomized, double blinded parallel-group controlled study. The purpose of this study is to evaluate efficacy, safety, and tolerability of repeated, daily sessions with the STARSTIM device, which delivers…
- Conditions
- Refractory Epilepsy, Focal Seizure, Seizures, Focal, Seizures
- Trial name
- NCT04770337
- Testing
- STARSTIM device
- Where
- 32 sites in United States, Belgium and 2 more
- Volunteers
- 127 people
- Sponsor
- Neuroelectrics Corporation
Highly Drug-resistant Focal Epilepsy
A Study of UCB0942 in Adult Patients With Highly Drug-resistant Focal Epilepsy
This study is to assess the efficacy, safety, and tolerability of the investigational drug UCB0942in adult subjects with drug-resistant focal epilepsy across multiple centers in Europe.
- Trial name
- NCT02495844
- Testing
- UCB0942
- Where
- 18 sites in Belgium, Bulgaria and 4 more
- Volunteers
- 55 people
- Sponsor
- UCB Biopharma S.P.R.L.
Refractory Partial Seizures
Evaluating the Efficacy and Safety of E2007 (Perampanel) Given as Adjunctive Therapy in Subjects With Refractory Partial Seizures
The purpose of this study is to evaluate the safety, efficacy and tolerability of perampanel when given as an adjunctive therapy in subjects with refractory partial seizures.
- Trial name
- NCT00699972
- Testing
- E2007 (perampanel)
- Where
- 97 sites in United States, Argentina and 4 more
- Volunteers
- 390 people
- Sponsor
- Eisai Inc.
Epilepsy, Focal-Onset Seizure
A Real World Study on the Efficacy and Safety of Lacosamide as Add-on Therapy for Focal-onset Epilepsy
The purpose of this trial is to evaluate the efficacy, safety, and pharmaco-economics of Lacosamide Tablet as first add-on therapy for uncontrolled focal onset epilepsy ,invetigating effects of lacosamide Tablet on cognitive…
- Trial name
- NCT04737837
- Testing
- lacosamide
- Where
- 19 sites in China
- Volunteers
- 200 people
- Sponsor
- Jiangxi Qingfeng Pharmaceutical Co. Ltd.
Epilepsy, Seizures
A Study on Safety and Efficacy of Two Doses of Topiramate as Monotherapy in the Treatment of Newly Diagnosed or Recurrent Epilepsy
The purpose of this study is to compare the safety and effectiveness of two doses of topiramate as monotherapy in the treatment of pediatric and adult patients with newly diagnosed or recurrent epilepsy.
- Conditions
- Epilepsy, Seizures, Epilepsies, Partial, Epilepsy, Generalized
- Trial name
- NCT00231556
- Testing
- topiramate
- Volunteers
- 750 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Epilepsy, Partial, Motor, Epilepsy, Complex Partial
An Open-Label Extension Study of the Safety and Tolerability of Carisbamate as Add-On Therapy in Patients With Partial Onset Seizures
The purpose of this study is to obtain long-term safety and tolerability information on carisbamate as add-on therapy for the treatment of partial onset seizures in patients with epilepsy.
- Conditions
- Epilepsy, Partial, Motor, Epilepsy, Complex Partial, Epilepsy, Simple Partial, Focal Motor Epilepsy
- Trial name
- NCT00744731
- Testing
- carisbamate
- Volunteers
- 403 people
- Sponsor
- SK Life Science, Inc.
Epilepsy
Embrace: Seizure Characterization
The study is intended to characterize sleep, stress, and seizures in daily life with the Empatica Embrace watch and smartphone-based diary-alert system.
- Trial name
- NCT03206502
- Testing
- Embrace + Alert App
- Volunteers
- 100,000 people, healthy volunteers welcome
- Sponsor
- Empatica, Inc.
Seizures
Pregabalin In Partial Seizures: An Open-Label, International, Multicenter Add-On Therapy Trial.
To assess the clinical improvement (change in seizure frequency), safety and tolerability of patients with partial seizures following adjunctive therapy of pregabalin BID in addition to existing standard AEDs.
- Trial name
- NCT00141427
- Testing
- Pregabalin
- Where
- 57 sites in Belgium, Finland and 6 more
- Volunteers
- 540 people
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.